pep

Pep-1 (uncapped), which has 21 amino acid residues, is a known carrier peptide that delivers full-length native proteins in vitro and in vivo.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Potent inhibitor of PCSK9 binding to LDL receptor (IC50 = 0.8 μM). Restores LDL uptake in HepG2 cells treated with PCSK9.

Pep 2-8 ammonium salt is Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Potent inhibitor of PCSK9 binding to LDL receptor (IC50 = 0.8 μM). Restores LDL uptake in HepG2 cells treated with PCSK9.

pep2-EVKI is an inhibitor peptide that selectively disrupts binding of the AMPA receptor subunit GluA2 (at the C-terminal PDZ site) to protein interacting with C kinase (PICK1). Does not affect binding of GluA2 to GRIP or ABP and does not increase AMPA current amplitude or affect long term depression (LTD).

Pep2-EVKI acetate is a cell-permeable peptide. Pep2-EVKI acetate interferes the interaction between protein interacting with C-kinase (PICK1) and GluR2 AMPA receptor subunits.

Cell-permeable, myristoylated form of pep2m. Peptide inhibitor of the interaction between the C-terminus of the GluA2 (AMPA receptor) subunit and N-ethylmaleimide-sensitive fusion protein (NSF), a protein that regulates AMPA receptor function. Reduces pos

Peptide R54 (Pep R54; CXCR4 antagonist peptide 19) is an antagonistic polypeptide targeting CXCR4, known for its significant anticancer properties. It inhibits CXCR4-dependent cell migration, epithelial-mesenchymal transition, and the development of lung metastasis, offering better serum stability and higher CXCR4 affinity (IC50=20 nM) compared to the lead compound. Peptide R54 works synergistically with anti-PD-1 therapy to exhibit antitumor effects in vivo, enhancing granzyme activity and reducing Foxp3 cell infiltration. It is useful for research in colon cancer, ovarian cancer, and melanoma.

Pep-1-Cysteamine, a chimeric cell-penetrating peptide (CPP), exhibits primary amphipathicity and facilitates the translocation of active proteins across biological membranes into cells [1].

Pep-1-Cysteamine TFA is a chimeric cell-penetrating peptide (CPP) with primary amphipathic properties. It possesses the capability to traverse biological membranes and facilitate the intracellular delivery of active proteins.

Pep-20 is a CD47/SIRPα blocking peptide with KD values of 2.91 μM for human CD47 and 3.63 μM for mouse CD47. It inhibits the CD47/SIRPα interaction with IC50 values of 24.56 μM for humans and 12.03 μM for mice. Pep-20 also exhibits antitumor activity.

DOTA-Pep-1L TFA is a peptide resulting from the conjugation of DOTA with Pep-1L, where Pep-1L specifically targets the IL13RA2 receptor. DOTA-Pep-1L TFA is utilized in PET imaging and research on tumor-targeted therapies.

DOTA-Pep-1L is a peptide formed by the conjugation of DOTA with Pep-1L, where Pep-1L is a peptide specifically targeting the IL13RA2 receptor. DOTA-Pep-1L is applicable in PET imaging and research focused on tumor-targeted therapy.

pep2m aceate is a Peptide inhibitor of the interaction between the C-terminus of the GluR2 subunit and N-ethylmaleimide-sensitive fusion protein

pep2-AVKI is an inhibitor peptide that selectively disrupts binding of the AMPA receptor subunit GluA2 (at the C-terminal PDZ site) to protein interacting with C kinase (PICK1). Does not affect binding of GluA2 to GRIP or ABP and does not increase AMPA current amplitude or affect long term depression (LTD).

pep2-AVKI acetate(1315378-69-8 free base) An inhibitor peptide that selectively disrupts binding of the AMPA receptor subunit GluA2 (at the C-terminal PDZ site) to proteins that interact with C-kinase (PICK1). Does not affect GluA2 binding to GRIP or ABP, nor does it increase AMPA current amplitude or affect long-term depression (LTD).

Inhibitor peptide corresponding to last 10 amino acids of the C-terminus of the GluA2 AMPA receptor subunit. Disrupts binding of GluA2 (at the C-terminal PDZ site) with glutamate receptor interacting protein (GRIP), AMPA receptor binding protein (ABP) and

Pep2-SVKI acetate(pep2-SVKI acetate (328944-75-8 free base)) is a synthetic peptide salt that prevents internalization of AMPA-type glutamate receptor.

Pep2m, myristoylated acetate is a Cell-permeable, myristoylated form of pep2m. Peptide inhibitor of the interaction between the C-terminus of the GluA2 (AMPA receptor) subunit and N-ethylmaleimide-sensitive fusion protein (NSF), a protein that regulates A

Analog of Pep1-TGL

Peptide containing the 'TGL' motif that corresponds to the C-terminus of GluR1 subunit

Myristoylated TFA Pep2m (Myr-Pep2m TFA) is a cell-permeable peptide that effectively disrupts the interactions between the protein kinase ζ (PKMζ) downstream targets—N-ethylmaleimide-sensitive factor/glutamate receptor subunit 2 (NSF/GluR2). PKMζ, an autonomously active isozyme of protein kinase C (PKC), plays a crucial role in these interactions [1] [2].

Pep19-2.5, a synthetic antitoxin peptide, inhibits the intracellular signaling cascade triggered by endotoxins by blocking the activity of lipopeptides (LP) and lipopolysaccharides (LPS) mediated through both transmembrane and cytosolic pattern recognition receptors (PRRs). This action disrupts the signaling pathways that normally result in inflammation and cell pyroptosis [1].

Pep2-8 is a peptide that has demonstrated enhanced antagonistic activity against proprotein convertase subtilin/kexin type 9 (PCSK9) [1].

PEP1 is a biologically active peptide that interacts with POPC supported lipid bilayers (SLBs), binding at low concentrations, while higher concentrations induce POPC SLB lysis.